Yes — your primary care doctor can prescribe GLP-1 medications. There's no specialist gatekeeping requirement. Any licensed physician (MD or DO), nurse practitioner, or physician assistant with prescriptive authority can write a prescription for semaglutide or tirzepatide. So why does it sometimes feel impossible to get one from your PCP?
Why PCPs Hesitate
The most common reason primary care physicians don't prescribe GLP-1s isn't clinical reluctance — it's administrative burden. Prior authorization for brand-name GLP-1 medications is notoriously time-consuming. Insurers require documentation of BMI, comorbidities, failed diet attempts, and sometimes prior medication trials before approving coverage. This process takes 2–8 weeks and has a first-attempt denial rate of 30–60% depending on the insurer.
Many PCP offices don't have the staffing to manage this paperwork, especially for a medication class that requires ongoing prior auth renewals. The result: your doctor may be willing to prescribe but tells you "we don't do that here" because the administrative overhead doesn't fit their workflow.
The second reason is clinical comfort. GLP-1 medications are relatively new for weight management — Wegovy was approved in 2021, Zepbound in 2023. Many PCPs trained before these drugs existed for obesity and may not feel confident managing dose titration, side effects, and the specific monitoring requirements. This is changing rapidly as continuing medical education catches up, but the gap still exists.
The Bottom Line
Your PCP can prescribe GLP-1 medications. No specialist referral is needed. But many PCP offices avoid it due to prior authorization burden and lack of familiarity. If your doctor says no, it's usually an administrative decision, not a medical one.
How to Ask Your PCP
Framing matters. Instead of asking "Can you prescribe Ozempic for weight loss?" — which may trigger a reflexive no — try a more specific approach. Share that you've researched GLP-1 medications, explain that you meet the prescribing criteria (BMI 30+ or 27+ with comorbidities), and ask if they'd be comfortable managing the prescription or if they'd prefer to refer you to an obesity medicine specialist.
Bringing recent lab work (A1C, lipid panel, metabolic panel) demonstrates that you're serious and prepared. Having a documented history of diet and exercise attempts — even informal ones — helps satisfy prior authorization requirements if you're pursuing insurance coverage.
PCP vs Telehealth vs Specialist: Tradeoffs
PCP prescription is the best path if you have a good relationship with your doctor and insurance coverage for GLP-1 medications. Your PCP knows your full medical history, can coordinate with your other medications, and can provide in-person follow-up. The downside is the prior authorization timeline and potential unfamiliarity with dose titration.
Telehealth platforms are the fastest path. No prior authorization for compounded medications, streamlined intake, and medication delivered to your door in under a week. The tradeoff is cost — you're paying out of pocket ($146–399/month typically) — and potentially less integration with your broader healthcare.
Endocrinologist or obesity specialist offers the deepest clinical expertise. They manage complex cases (diabetes co-management, post-bariatric patients, concurrent hormonal issues) and are most comfortable with aggressive dose titration. The downside is availability — many obesity specialists have 3–6 month wait lists.
The Insurance Question
This is often the deciding factor. If your insurance covers GLP-1 medications (and many do not for weight loss), going through your PCP or a specialist is the most cost-effective route — even with prior authorization hassles. If your insurance doesn't cover them, or the prior auth is denied, telehealth compounded medications bypass the insurance system entirely.
Check your formulary before making a plan. Call the number on your insurance card and specifically ask: "Is semaglutide or tirzepatide covered for weight management with an obesity diagnosis?" The answer will determine your best path forward.
Don't assume your insurance won't cover it. Coverage has expanded significantly in 2025–2026 as cardiovascular outcome data (SELECT trial) shifted the framing from "weight loss drug" to "cardiovascular risk reduction." Employers and insurers that previously excluded GLP-1 coverage are adding it. It's worth checking even if you were denied before.
Skip the Wait — Start Online
All providers are US-licensed telehealth platforms. State availability varies.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
⚠️ Disclosure: MEDVi received an FDA warning letter in February 2026 regarding product misbranding. Consumers should review this information before enrolling.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
What If Your PCP Says No?
If your primary care doctor declines to prescribe, you have options. Ask for a referral to an obesity medicine or endocrinology specialist. Try a different PCP — many large primary care practices have at least one physician who actively prescribes GLP-1 medications. Or use a telehealth platform for the prescription while keeping your PCP informed about the treatment — send them a summary of what you've been prescribed so it stays in your medical record.
The worst response to a PCP refusal is giving up. GLP-1 medications are the most effective pharmacological weight-loss intervention available. If you meet the criteria, you deserve access — whether through your PCP, a specialist, or a licensed telehealth provider.
Sources & References
- American Board of Obesity Medicine. Provider directory and prescribing statistics. 2025.
- KFF. Employer Coverage of GLP-1 Medications Survey. 2025.
- AMA. Reducing Administrative Burden: Prior Authorization Reform. 2024.
- Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes (SELECT Trial)." NEJM. 2023;389:2221–2232.
- Obesity Medicine Association. GLP-1 Prescribing Guidelines for Primary Care. 2025.